Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)
A Phase 2 Open Label, Single Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel as Neoadjuvant Therapy in Patients Undergoing Surgical Resection of Squamous Cell Carcinoma (SCC)
Sponsor: Kavita Sarin
Terminated
The available study medication reached expiry (logistics).
This PHASE2 trial investigates Squamous Cell Carcinoma and is currently terminated or withdrawn. Kavita Sarin leads this study, which shows 12 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jun 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Mar 2021 — Jun 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2019 — Jul 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kavita Sarin
- Medivir
For direct contact, visit the study record on ClinicalTrials.gov .